BofA lowered the firm’s price target on Sarepta (SRPT) to $210 from $217 and keeps a Buy rating on the shares. Management is confident in FY25 guidance given clear visibility, notes the analyst, who is “encouraged” by the strong commercial performance of the Elevidys launch to-date and what the firm sees as “the large potential commercial opportunity.” The firm currently models $4.3B in risk-adjusted peak sales for Elevidys, which contributes $147 per share to its price target for Sarepta.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $196 from $195 at Morgan Stanley
- Optimistic Buy Rating for Sarepta Therapeutics Driven by Elevidys Potential and Expanding Pipeline
- Sell Recommendation for Sarepta Therapeutics Amid Concerns Over ELEVIDYS Uptake and Coverage Limitations
- Sarepta Therapeutics: Strong Sales Growth and Promising Outlook Justify Buy Rating
- 3 Best Stocks to Buy Now, 2/27/2025, According to Top Analysts